Fig 4.

Survival after MP treatment is associated with differences in lipid and vitamin metabolism. (A) Differential abundance of metabolite features between MP-treated patients who died before or survived after 14 days at D1 and D5. (B) Venn diagram comparing significant metabolite features at D1 and D5. (C) Significant metabolic network associated with steroid hormone metabolism enriched by differentially abundant metabolite features at D1. (D) Mummichog pathway analysis of significant metabolite features at D1 and D5 for MP-treated patients who died before or survived after 14 days. (E) Differential abundance of annotated metabolites identified in MP-treated patients that survived compared to those who died before 14 days of treatment. *P < 0.05, **P < 0.01.